<DOC>
	<DOCNO>NCT01076036</DOCNO>
	<brief_summary>An open-label , prospective , single-arm study design evaluate safety , clinical technical efficacy CorPath 200 System delivery manipulation coronary guide wire balloon/stent system use robotically-assisted , percutaneous coronary intervention ( PCI ) procedure .</brief_summary>
	<brief_title>CorPath™ 200 : Robotically-Assisted Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description>Objective The study objective evaluate safety technical efficacy CorPath 200 System delivery manipulation commercially available coronary guidewires rapid exchange balloon/stent catheter use percutaneous coronary intervention ( PCI ) . I . Primary Endpoints A. Efficacy Device Clinical Success : Achievement &lt; 30 % final diameter stenosis utilize CorPathTM 200 System deliver PTCA balloon stent target lesion , successfully retract device without occurrence In-Hospital MACE ( Major Adverse Cardiac Event ) evaluate 48 hour post procedure hospital discharge , whichever occur first . B . Safety In-Hospital MACE : Defined composite death ( cause mortality ) , recurrent MI , target vessel revascularization ( emergent coronary artery bypass surgery [ CABG ] PCI ) evaluate 48 hour post procedure hospital discharge , whichever occur first . II . Secondary Endpoints A. Efficacy CorPath Success : Ability navigate guide wire balloon/stent system utilize CorPath™ device target site without occurrence In-Hospital MACE , evaluate 48 hour post index procedure hospital discharge , whichever occur first . Subject Clinical Success : Achievement &lt; 30 % final diameter stenosis target lesion treatment PTCA/coronary stent without occurrence In-Hospital MACE , evaluate 48 hour post-index procedure hospital discharge , whichever occur first . B . Safety : MACE 30 Days : Defined composite death , recurrent MI and/or target vessel revascularization ( emergent coronary artery bypass surgery [ CABG ] PCI ) evaluate 30 day post index procedure . Adverse Events : A summary adverse event observe trial summarize either serious non-serious summarize attribution . C. Clinical Utility Procedure Attributes : - Reduction radiation exposure primary operator base radiation dosimetry measurement procedure table primary operator . - Total Procedure time base time insertion hemostasis sheath time final guide catheter withdrawal . CorPath Device Attributes : Subjective assessment operator follow device performance attribute : - Movement guide wire ( rotate advance ) target . - Maneuvering position guide wire target . - Movement stent/balloon ( advance ) target . - Ability deliver PTCA/stent system intend target lesion . - Ease use system interventional team . Material &amp; Methods Corindus obtain approval ( CORBIC Ethics Committee INVIMA - Colombian Ministry Health ) 2009 conduct clinical study `` CorPath™ 200 System : Coronary Remote Catheterization Feasibility Study '' CORBIC Cardio-Neuro-Vascular Institute , Envigado , Colombia . The study single arm , open label , prospective registry treat de novo lesion ( 2.5 mm - 4.0 mm diameter , 25.0 mm length &gt; 50 % stenosis ) utilize CorPath 200 System deliver , manipulate retrieve guidewire balloon/stent catheter system .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>General The subject acceptable candidate PCI . The subject must clinical evidence ischemic heart disease positive functional study . Female subject must nonchild bear potential , able bear child , negative pregnancy test within seven ( 7 ) day prior index procedure . The subject legal representative inform nature study agree provision provide write informed consent . Angiographic Study lesion de novo native coronary artery lesion ( i.e. , coronary lesion previously treat ) The study lesion intend treat one stent . Maximum stent length allow 20 mm . The study reference vessel diameter 2.50 mm 4.5 mm visual estimate . Study lesion diameter show significant stenosis least 50 % visual estimate . General Subject require plan PCI CABG within 30 day follow index procedure . Subject evolve ST elevation myocardial infarction ( STEMI ) ( i.e. , begin MI symptom within 72 hour prior plan index procedure ) . Subject document left ventricular ejection fraction &lt; 30 % . Subject know hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , stainless steel , sensitivity contrast medium , adequately premedicated . Subject platelet count &lt; 100,000 cell/mm3 &gt; 700,000 cell/ mm3 , WBC &lt; 3000 cell/ mm3 ( e.g . thrombocytopenia , thrombocythemia , neutropenia leucopenia ) . Subject history stroke ( CVA ) TIA within 30days prior plan index procedure . Subject active peptic ulcer upper GI bleeding within 6 month prior plan index procedure . Subject history bleed diathesis coagulopathy refuse blood transfusion . Subject currently participate another investigational drug l drug device trial complete entire follow period . Angiographic Study lesion fully cover single stent maximal length Subject require treatment multiple lesion study vessel time index procedure . The study lesion require plan treatment DCA , laser , rotational atherectomy , device except balloon dilatation prior stent placement . The study vessel evidence intraluminal thrombus moderate severe tortuosity ( &gt; 90o ) proximal target lesion . The study lesion follow characteristic : 1 . Total occlusion 2 . Ostial location 3 . Involves side branch &gt; 2.0 mm vessel diameter 4 . Is locate &gt; 45° bend vessel 5 . Is moderately severely calcified 6 . Moderatetosevere calcification part vessel prior target lesion Unprotected leave main coronary artery disease ( obstruction great 50 % diameter stenosis leave main coronary artery ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ischemia</keyword>
	<keyword>stent</keyword>
</DOC>